Research
Hormonal
PYY3-36, released from intestinal L-cells after meals, acts as an anorexigenic signal by inhibiting ARC Y2 receptors, leading to increased alpha-MSH and reduced NPY release, thereby reducing appetite.
PYY3-36 is a hormone released by your gut after eating that helps signal fullness to your brain. It works by inhibiting hunger signals (NPY) and promoting satiety signals (alpha-MSH). Diets rich in protein and fiber may naturally boost PYY release, aiding satiety.
GoodSupportsHIGH confidence
PYY3-36... exerts a direct action in the ARC... increases neuronal activity in this region and reduces appetite and body weight in a dose-dependent manner... These anorexigenic effects are mediated via the inhibition of ARC Y2 receptors... which eventually leads to increased a-MSH and reduced NPY release.
Why this rating
Supported by pharmacological and genetic studies showing dose-dependent effects.
Source
Hypothalamic and brainstem neuronal circuits controlling homeostatic energy balance
Marc Schneeberger et al. · Journal of Endocrinology · 2013
DOI 10.1530/joe-13-0398
narrative_reviewCited 289×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Leptin acts as an anorexigenic signal by binding to LEPRb in the hypothalamus, activating the JAK2/STAT3 and PI3K pathways to stimulate POMC and inhibit AgRP neurons, thereby reducing food intake and increasing energy expenditure.Strong
- Ghrelin acts as an orexigenic signal by binding to GHSR on AgRP neurons in the arcuate nucleus, stimulating NPY and AGRP expression and increasing food intake and adiposity.Strong
- GLP1, secreted from intestinal L-cells after meals, acts as an anorexigenic signal by activating GLP1 receptors in the hypothalamus and brainstem, inhibiting food intake via vagal afferents and central circuits.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →